Compare LPCN & MDRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPCN | MDRR |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1M | 18.3M |
| IPO Year | 2011 | N/A |
| Metric | LPCN | MDRR |
|---|---|---|
| Price | $2.36 | $11.21 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 64.8K | 3.4K |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.43% |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,976,677.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $92.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $9.47 |
| 52 Week High | $12.37 | $14.52 |
| Indicator | LPCN | MDRR |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 48.15 |
| Support Level | $2.16 | $10.85 |
| Resistance Level | $2.46 | $12.02 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 6.25 | 30.11 |
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.